BMJ open gastroenterology

How GLP-1-based treatment relates to small bowel movement speed during capsule endoscopy

Updated

Abstract

The study evaluates the association between glucagon-like peptide-1 (GLP-1) therapy and small-bowel transit time during capsule endoscopy.

  • GLP-1 is a hormone involved in regulating blood sugar and digestion.
  • Small-bowel transit time refers to how long it takes food to move through the small intestine.
  • Capsule endoscopy is a non-invasive procedure that captures images of the small intestine.
  • The potential link between GLP-1 therapy and altered small-bowel transit time is being explored.
  • Findings may provide insights into how GLP-1 therapy affects digestive processes.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

No competing interests reported.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free